west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "陈积圣" 5 results
  • Basic and Clinical Research of Splenic Autotransplantation and Oesophageal Transection Anastomosis in Patients with Portal Hypertension:30 Years Observation of a New Treatment Strategy

    Release date: Export PDF Favorites Scan
  • EFFECTS OF SPLENECTOMY ON ANTI-TUMOR IMMUNITY DURING THE INDUCTION OF HEPATOCELLULAR CARCINOMA IN RATS

    Objective To study the effect of splenectomy on the anti-tumor immunity in rats with induced hepatocellular carcinoma (HCC). Methods At the second and fourth month of the induced HCC, the NK cell activity, TNF-α level and total lymphcyte in blood were measured in the group of splenectomy and the control group. Results There were no different in the total lymphcyte and TNF-α in the blood in two groups, but there were significant difference in the NK cell activity between the group of splenectomy and the control group (P<0.05). Conclusion There are some change in the anti-tumor immunity after splenectomy in rats, in which NK cell activity is at low level continuously. TNF-α isn′t affected after the second month after splenectomy.

    Release date:2016-09-08 02:00 Export PDF Favorites Scan
  • Expression and Significance of Livin in Human Cholangiocarcinoma Tissues and Cell Line

    目的:探讨Livin基因在人胆管癌组织及胆管癌细胞系中的表达情况及其与胆管癌发 生发展之间的关系。方法:采用免疫组织化学技术(SP法)检测Livin基因蛋白在45例人胆管 癌标本及及40例癌旁胆管组织、20例正常胆管组织标本中的表达;同时采用RTPCR法及SP 法检测了Livin基因mRNA和蛋白在人胆管癌细胞系QBC939及非肿瘤细胞系HT1080中表达。 结果:Livin在胆管癌组织中表达阳性率为57.8%,而癌旁胆管组织、非癌胆管组织中未能检 测到Livin表达。Livin表达与性别、年龄、肿瘤大小及肿瘤分化程度无关。在有淋巴结转组 中,Livin阳性表达率(70.4%)明显高于无淋巴结转移组(38.9%)。在人胆管癌细胞QBC939 中,Livin mRNA及蛋白均特异性表达,而非肿瘤细胞系HT1080未见Livin表达。结论:Livin 基因在人类胆管癌组织和细胞系中选择性高表达,其可能与胆管癌发生、发展及预后密切相 关。

    Release date:2016-08-26 03:57 Export PDF Favorites Scan
  • 胰十二指肠术中门静脉损伤的预防及修复

    Release date:2016-09-01 11:05 Export PDF Favorites Scan
  • Clinical Study of Retroperitoneal Splenic Autotransplantation Combined with Lower Esophagus Transection in Treatment of Hepatic Cirrhosis Induced Portal Hypertension

    【Abstract】ObjectiveTo inquire the therapeutic effect of retroperitoneal splenic autotransplantation combined with lower esophageal transection in the treatment of hepatic cirrhosis induced portal hypertension with randomized comparasion.MethodsThe hepatic cirrhosis induced portal hypertension patients with Child A or B grade of liver function were randomly divided into splenic autotransplantation group and splenectomy group.In the splenic autotransplantation group, retroperitoneal transplantation of pedicled autosplenic tissue combined with modified lower esophageal transection was performed,while in the splenectomy group, splenectomy combined with modified lower esophageal transection was conducted.The general conduction, splenic scanning, liver function, serum tuftsin and IgM levels in patients were observed 2 to 6 months after operation, and compared with those before operation. ResultsOne patient died in the splenectomy group on the 6th postoperative day, rebleeding occurred in one case of the splenic autotransplantation group. The levels of tuftsin and IgM in splenic autotransplantation group were higher than those of splenectomy group after operation, with significant difference (P<0.01). The liver function between two groups showed no difference (Pgt;0.05).ConclusionSpleen autografts could maintain the basic immune function of spleen and survive for a long time.

    Release date:2016-09-08 11:54 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content